机构:
Univ Texas Hlth Sci Ctr San Antonio, Dept Radiat Oncol, Canc Therapy & Res Ctr, San Antonio, TX 78229 USAUniv Texas Hlth Sci Ctr San Antonio, Dept Radiat Oncol, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA
Ramahi, Emma
[1
]
Choi, Jehee
论文数: 0引用数: 0
h-index: 0
机构:
Univ Texas Hlth Sci Ctr San Antonio, Dept Radiat Oncol, Canc Therapy & Res Ctr, San Antonio, TX 78229 USAUniv Texas Hlth Sci Ctr San Antonio, Dept Radiat Oncol, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA
Choi, Jehee
[1
]
Fuller, Clifton D.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Texas Hlth Sci Ctr San Antonio, Dept Radiat Oncol, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA
Univ Texas Hlth Sci Ctr San Antonio, Human Imaging Program, Div Radiol Sci, Dept Radiol, San Antonio, TX 78229 USAUniv Texas Hlth Sci Ctr San Antonio, Dept Radiat Oncol, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA
Fuller, Clifton D.
[1
,2
]
Eng, Tony Y.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Texas Hlth Sci Ctr San Antonio, Dept Radiat Oncol, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA
Univ Texas Hlth Sci Ctr San Antonio, Human Imaging Program, Div Radiol Sci, Dept Radiol, San Antonio, TX 78229 USAUniv Texas Hlth Sci Ctr San Antonio, Dept Radiat Oncol, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA
Eng, Tony Y.
[1
,2
]
机构:
[1] Univ Texas Hlth Sci Ctr San Antonio, Dept Radiat Oncol, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA
[2] Univ Texas Hlth Sci Ctr San Antonio, Human Imaging Program, Div Radiol Sci, Dept Radiol, San Antonio, TX 78229 USA
来源:
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
|
2013年
/
36卷
/
03期
Merkel cell carcinoma (MCC) is a rare, clinically aggressive cutaneous neuroendocrine neoplasm with a high mortality rate. Though the etiology is not precisely known, Merkel cell polyomavirus DNA has been found recently in a large percentage of MCC tumors. Other suggested risk factors include sun exposure, immunosuppression, and a history of prior malignancy. Work up of patients with MCC most notably includes nodal staging via clinical examination or sentinel lymph node biopsy. The prognosis for most patients with MCC is poor, and the rarity of MCC precludes the prospective, randomized clinical trials necessary to elucidate optimum treatment protocols. Most published data support the use of a multimodality approach centered around surgical excision with negative margins, sentinel lymph node biopsy to establish the presence or absence of nodal metastases, adjuvant radiothearpy to decrease the risk of recurrence, and systemic chemotherapy in the case of widespread disease.